Presentation of a Meningioma in a Transwoman After Nine Years of Cyproterone Acetate and Estradiol Intake: Case Report and Literature Review
November 2017
in “
Gynecological Endocrinology
”
TLDR A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.
In 2017, a case report detailed a 41-year-old transwoman who developed a meningioma after nine years of hormone treatment with cyproterone acetate (CPA) and estradiol. The tumor, which was positive for progesterone and estrogen receptors, was discovered incidentally and subsequently removed after discontinuing CPA. Post-surgery, the patient was treated with leuprorelina acetate and estradiol, with no recurrence at the one-year mark. This case contributes to a small but growing body of evidence suggesting a link between high-dose CPA, a common component of hormone therapy for transwomen, and the development of meningiomas. The authors recommend careful documentation of such cases and consideration of alternative hormone therapies that may pose a lower risk of meningioma formation.
